{"meta":{"query_hash":"0e3bef5e8e27","filters":{"venue":"Journal of Skin and Stem Cell"},"cohort_total":1,"direct_labels_cover":0,"predictions_cover":1,"exported":1,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/0e3bef5e8e27","api":"https://metacan.xera.ac/api/v1/cohort?venue=Journal+of+Skin+and+Stem+Cell"},"results":[{"id":"W4416796876","doi":"10.5812/jssc-166700","title":"Baricitinib in Dermatology: Expanding Therapeutic Horizons Beyond Alopecia Areata","year":2025,"lang":"","type":"article","venue":"Journal of Skin and Stem Cell","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Alopecia areata; Atopic dermatitis; Janus kinase; Tofacitinib; Clinical trial; Dupilumab; STAT protein; Immune dysregulation","score_opus":0.012074404537594364,"score_gpt":0.27618802888850325,"score_spread":0.2641136243509089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416796876","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00094982056,0.9943718,0.00012731057,0.0019994641,0.00027151743,0.000017107583,0.00008811812,0.000008273279,0.0021666216],"genre_scores_gemma":[0.0086171925,0.9888207,0.0003323558,0.0012384439,0.00053612044,0.000014966547,0.000089244946,0.0000024560354,0.00034854078],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9995653,0.00014426073,0.00009104494,0.000043401804,0.00012455981,0.00003142285],"domain_scores_gemma":[0.998425,0.00097281794,0.0003355156,0.000021465687,0.00019738595,0.00004785216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010878977,0.00035723398,0.0011222984,0.00228086,0.00022674786,0.0014832357,0.0003884388,0.00084695057,0.0043783872],"category_scores_gemma":[0.0022357842,0.00011630309,0.0008198387,0.0021563966,0.00032386044,0.0014934714,0.0005917695,0.0009208956,0.0006083919],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002843988,0.00006778217,0.0008264086,0.17140189,0.0004228225,0.0006118583,0.00023786079,0.00034749645,0.0022904351,0.006233504,0.025459142,0.7918165],"study_design_scores_gemma":[0.00017596319,0.00045445966,0.005186083,0.16717704,0.0021080645,0.0048682275,0.0005928872,0.00036618274,0.0010266589,0.0052909846,0.81270075,0.000052680884],"about_ca_topic_score_codex":0.000928979,"about_ca_topic_score_gemma":0.0029768336,"teacher_disagreement_score":0.0043783872,"about_ca_system_score_codex":0.00065119995,"about_ca_system_score_gemma":0.0023379226,"threshold_uncertainty_score":0.014647126},"labels":[],"label_agreement":null}]}